"T reasure your exceptions! When there are none, the work gets so dull that no one cares to carry it further. Keep them always uncovered and in sight. Exceptions are like the rough brickwork of a growing building which tells that there is more to come and shows where the next construction is to be. " Geneticist William Bateson offered this advice in 1908, around the dawn of mod ern genetics following the rediscovery of Gregor Mendel's pea plant experiments, and it remains sound today.
Every empiricist must contend with exceptions to the rule, which can illuminate research in unpredictable ways. Bateson was urging vigilance in observing rare offspring of plants and animals, which may point to new phenomena that can inform us about the broader biological con text. The same is true for rare diseases, which often have a genetic basis.
This being a leap year, the extra day, 29 February, was designated Rare Disease Day. It aims to give a voice to the families of millions of exceptional children who are born each year with a rare or undiag nosed disease. Liddle syndrome and Tangier disease, for example,
The darker side of stem cells
An investigation by Nature has found that patients in Texas are receiving unproven stem-cell treatments. The state and the company involved need to ensure that they follow FDA guidelines. S tem cells offer the hope that one day they will be able to cure a huge range of disorders. But too many people are promising those cures to patients now, long before there is any evidence that they work. These claims are potentially misleading at best, and at worst could be downright harmful.
This week, Nature raises important questions about one company that works with adult stem cells: Celltex Therapeutics in Houston, Texas. Nature's investigation, reported on page 13, suggests that the company has supplied adult stem cells to Texas doctors who offer unproven treatments to patients, and that the company is involved in these treatments. One doctor claims that the treatments are part of a clinical study run by Celltex and that the company pays him US$500 a time to inject the cells into patients, who are charged up to $25,000 for a course. The US Food and Drug Administration (FDA) considers it to be a crime to inject unapproved adult stem cells into patients. David Eller, chief executive of Celltex, denies that the company is involved in treatment procedures, but would not comment on Nature's findings about how its cells are used or answer questions about them.
Celltex has the backing of state governor Rick Perry, who has tried adultstemcell treatments himself. And the company recently recruited Glenn McGee, editorinchief of the American Journal of Bioethics, to be its president of ethics and strategic initiatives. McGee, whose move from the academic world to industry sparked a controversy over a per ceived conflict of interest (see Nature 482, 449-450; 2012) , promises that Celltex will set up and run clinical trials, and will do so according to strict ethical standards. But he too would not answer Nature's questions on whether the company knew about the unapproved clinical use of its stem cells or whether he considered such activity to be ethical and legal.
There is an ethical paradox here. How can Celltex propose clinical trials for stemcell treatments while at the same time it is, according to a doctor involved, paying physicians to use those treatments -or sup plying cells to doctors who would no doubt use them -in the clinic? Shouldn't clinical trials be done before a treatment is given to paying patients? Conversely, if a treatment is known to be safe and effective enough to be prescribed routinely, and for a sizeable fee, what is the point of doing a costly clinical trial?
The questions do not stop at Celltex. The governorappointed Texas Medical Board is set to launch regulations in April to tighten controls on the use of 'investigational agents' -such as stem cells that do not have FDA approval. But the board is simultaneously offering an alter native route by proposing that those who want to use adultstemcell treatments need either FDA approval or simply the approval of a local institutional review board.
Texas officials should take the FDA's regulatory power over stem cells more seriously. In its discussions, the state's medical board revisited the welltrodden ground of whether adultstemcell procedures -in which cells are taken from a patient, processed and cultured, before being reintroduced -should be under FDA jurisdiction, or whether they are akin to simple skin grafts from one part of the body to another, which do not require validation in an FDAapproved clinical trial.
The FDA can help to clarify these matters. A sensible first step in the new state regulations would be a requirement for any firm that plans to inject processed stem cells into patients to contact the FDA, which can advise on whether federal rules -the same federal rules that have already been used to arrest stemcell practitioners and to stop a company pushing unapproved treatments elsewhere -apply to what they are doing. Once past that step, Texas could move on to develop its own safety regulations. If the Texas Medical Board were to act according to its stated pledge to protect patients, then it would make clear the need for clinical validation of adult stem cells before use and would rescind the medical licences of any doctors in breach of rules on using unapproved treatments. If Celltex truly wants to help patients, then it should refuse to supply stem cells for medical procedures until those procedures are properly proven to be effective. And if the com pany is serious about demonstrating clinical effectiveness itself, then it should start by contacting the FDA about what needs to be done. 
Frozen out
Canada's government should free its scientists to speak to the press, as its US counterpart has. M edia interactions with government scientists have undergone a reversal across North America during the past six years. In the United States, President Barack Obama's administra tion has directed federal science agencies to develop integrity policies with clear guidelines for scientists who are approached by journalists.
In December, agencies including the US National Science Founda tion (NSF) and the US National Oceanic and Atmospheric Admin istration (NOAA) issued guidelines that promote openness with the press. For instance, NOAA and NSFfunded scientists and staff are free to speak to journalists without first seeking the approval of a publicaffairs officer. The NSF's policy states that researchers are free to express their personal views as long as they make clear that they are not speaking on behalf of the agency. And scientists also have right of review over agency publications and press releases that claim to rep resent their expert opinions. Such policies may not be implemented successfully in all cases, but they show that attitudes have evolved encouragingly since 2006, when charges that thenpresident George W. Bush's administration had silenced US government researchers made frontpage news.
Over the same period, Canada has moved in the opposite direction. Since Prime Minister Stephen Harper's Conservative Party won power in 2006, there has been a gradual tightening of media protocols for federal scientists and other government workers. Researchers who once would have felt comfortable responding freely and promptly to journalists are now required to direct inquiries to a mediarelations office, which demands written questions in advance, and might not permit scientists to speak. Canadian journalists have documented sev eral instances in which prominent researchers have been prevented from discussing published, peerreviewed literature. Policy direc tives and emails obtained from the government through freedom of information reveal a confused and Byzantine approach to the press, prioritizing message control and showing little understanding of the importance of the free flow of scientific knowledge.
The Harper government's poor record on openness has been raised by this publication before (see K. O'Hara Nature 467, 501; 2010), and Nature's news reporters, who have an obvious interest in access to scientific information and expert opinion, have experienced directly the cumbersome approval process that stalls or prevents meaningful contact with Canada's publicly funded scientists. Little has changed in the past two years: rather than address the matter, the Canadian government seems inclined to stick with its restrictive course and ride out all objections.
That position is coming under increasing pressure as a result of the scientificintegrity policies taking shape across the border. The clarity of the US guidelines undercuts the Canadian government's assertion that its own media policies are adequate and have simply been mis understood. If the Harper government truly embraces public access to publicly funded scientific expertise, then it should do what the Cana dian Science Writers' Association and several other organizations have called for in a letter sent to the prime minister on 16 February: "imple ment a policy of timely and transparent communication" like those used by NOAA and the NSF.
The letter coincided with a symposium, 'Unmuzzling Govern ment Scientists: How to Reopen the Debate' , which was held last week at the meeting of the American Association for the Advance ment of Science in Vancouver, Canada. With the country taking centre stage as the meeting's host, the Harper government found its media policies in the international spotlight. Scientists and other visitors from around the globe discovered, to their surprise, that Canada's generally positive foreign reputation as a progressive, scientific nation masks some startlingly poor behaviour. The way forward is clear: it is time for the Canadian government to set its scientists free. ■ affect a tiny number of people, especially compared with high blood pressure, diabetes or heart disease. The attention these rare disorders receive from pharmaceutical programmes, the medical community and academic research has historically been correspondingly small, despite the significant disease burden they bring to the healthcare systems of many countries. Perhaps up to onefifth of paediatric hospital admissions world wide are the result of Mendelian disorders -uncommon diseases that follow inheritance patterns outlined by Mendel in the nineteenth century, usually caused by mutations in a single gene. If not deadly, these conditions often demand expensive lifelong care.
Beyond the economic factors are the harrowing stories of parents trying to find treatment or even a diagnosis for a child with an excep tional problem. For rare diseases for which there are perhaps only one or two experts in the world, it typically takes a broad network of parents working together for the families to find help, or even infor mation.
The rapid rise of genome sequencing and its increasing use in pae diatric clinics offers some hope. Children with known diseases can be diagnosed faster than before, and those with previously unknown syndromes might be able to get a better understanding of the reason for their illness.
Rare disorders have conventionally been used to sharpen the tools of genetic medicine. Diseases that affect several families are prime targets for unpicking and understanding the effects of human gene mutations. With the development of better tools, researchers are now equipped to tackle even the rarest disorders. As the price of sequencing drops and analysis tools become more sophisticated, fewer individuals are needed to pin down the common genetic cause.
As the News Feature on page 20 highlights, one small clinic serv ing Amish and Mennonite communities in the United States is at the forefront of these efforts. Through sequencing and other tools, the paediatricians there estimate that they can discover 5-15 new disorders per year. They think that about half should be treatable if the underlying cause is identified early. The clinic is in an exceptional position, however. The communities it serves come from small founder populations, have a good knowledge of family history and a high rate of intermarriage. All of this makes unravelling the genetics of disease easier than in a more diverse population. But there are two reasons to treasure these exceptions. First, genetic disease has a long history of teaching scientists about normal biological processes, and can sometimes give insight into the processes that go awry in other, more common diseases. Liddle syndrome, for example, is one of several genetic disorders in which high blood pressure is a major defining factor. Tangier disease causes low levels of 'good' cholesterol in the blood, and many of those affected have premature atherosclerosis.
The second reason relates to a growing appreciation of the hetero geneity of 'common' diseases. Projects that sequence tumour genomes from dozens of patients -who by standard diagnostic measures have the same cancer, and thus the same disease -have revealed that each tumour has unique and divergent genetic properties. Indeed, the real work may begin once we realize that every case is an exception. ■ "Genetic disease has a long history of teaching scientists about normal biological processes."
